设为首页         

资讯内容 Content

[IHF2011]冠心病介入治疗中支架选择策略及并发症——Prof. Ting 专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

作者:HenryH.Ting 编辑:国际循环网 时间:2011/8/25 16:18:20    加入收藏
 关键字:冠心病介入治疗 PCI 药物洗脱支架 DES 金属裸支架 BMS Prof. Ting 

    Henry H.Ting  美国梅奥医学中心

    <International Circulation>: What are the common types of coronary stents currently used in clinical practice? For each, could you summarize their advantages and disadvantages? 

  《国际循环》:目前临床应用的冠脉支架有哪些类型?您来谈谈每种类型的优缺点有哪些?
    Prof Ting: The two most common types of coronary stents we use in clinical practice in the United States as well as China are drug-eluting stents and bare-metal stents. The main benefit of drug-eluting stents is the decrease in the risk of restenosis. Restenosis occurs when the blockage which has been treated returns within the first six to twelve months. The drug-eluting stents have revolutionized our treatment with coronary stents by decreasing that rate from approximately 15% - 30% with bare-metal stents to about 5% - 10% with drug-eluting stents. That is the main advantage of drug-eluting stents. That does come with a cost. With the drug-eluting stents, you have to take blood thinners, notably aspirin and clopidogrel, continuously for twelve months. If you stop that therapy, you are at very high risk of developing a blood clot in that stent. That is the main downside of using drug-eluting stents. The bare-metal stents have been around since 1994 and when they were originally introduced they revolutionized the way we treated coronary artery disease and blockages. The bare-metal stents have a higher risk of restenosis (as I said, 15%-30% as opposed to 5%-10%) but the good thing about bare-metal stents is that the risk of a blood clot is much lower and blood thinning medication (aspirin and clopidogrel) is only required for one month. In this day and age, I would estimate that about 75%-80% of procedures that will relieve blockages in coronary arteries are done with drug-eluting stents and 15%-20% done with bare-metal stents.

    Prof Ting:在中-美两国最常应用的支架不外乎药物洗脱支架(DES)和金属裸支架(BMS)。DES最大的优点在于有效降低再狭窄风险,而再狭窄的发生最常见于术后6-12个月。DES的应用无疑是支架技术革新的里程碑,它将BMS支架内再狭窄15-30%的数据减少到5-10%。但DES的应用会增加治疗费用,患者必须在术后坚持抗血小板治疗,持续服用阿司匹林,氯吡格雷至少12个月。如果间断药物治疗,支架内血栓的风险将大大增高,这是DES最大的劣势。BMS开始应用于1994年,开创了介入治疗冠脉疾患和狭窄的先河。BMS的缺点在于再狭窄率高(我之前所言相对于DES它的发生率为15%-30% vs 5%-10%),优点在于其支架内血栓风险低,且术后仅需服用阿司匹林和氯吡格雷片一个月。目前冠脉介入手术中大约有80%的手术会选用DES,而15-20%选用BMS。



[1]  [2]  [3]  下一页

 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved